[go: up one dir, main page]

CO4700302A1 - PREPARATION OF ALBUMIN FREE RECOMBINANT FACTOR WHICH HAS A LOW SUGAR CONTENT - Google Patents

PREPARATION OF ALBUMIN FREE RECOMBINANT FACTOR WHICH HAS A LOW SUGAR CONTENT

Info

Publication number
CO4700302A1
CO4700302A1 CO97039171A CO97039171A CO4700302A1 CO 4700302 A1 CO4700302 A1 CO 4700302A1 CO 97039171 A CO97039171 A CO 97039171A CO 97039171 A CO97039171 A CO 97039171A CO 4700302 A1 CO4700302 A1 CO 4700302A1
Authority
CO
Colombia
Prior art keywords
preparation
sugar content
low sugar
recombinant factor
free recombinant
Prior art date
Application number
CO97039171A
Other languages
Spanish (es)
Inventor
Nayar Rajiv
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CO4700302A1 publication Critical patent/CO4700302A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una preparación de rFVIII liofilizada, libre de albúmina,estable que comprende, cuando es reconstruída en agua, aproximadamente65 a 400 mM de glicina,hasta 50 mM de histidina,15 a 60 mM de sucrosa,hasta 50 mM de NaCl,hasta 5 mM de CaCl2 , y50 a 1500 IU rFVIII/ml.Una preparación de rFVIII liofilizada, libre de albúmina, estable que comprende, cuando es reconstruída con agua,290 mM de glicina,20 mM de histidina,30 mM de sucrosa,30 mM de NaCL,2.5 mM de CaCl2 , y50 a 1500 IU rFVIII/mlA stable, free-standing albumin-free lyophilized rFVIII preparation comprising, when reconstructed in water, approximately 65 to 400 mM glycine, up to 50 mM histidine, 15 to 60 mM sucrose, up to 50 mM NaCl, up to 5 mM of CaCl2, and 50 to 1500 IU rFVIII / ml. A stable, freeze-dried, albumin-free rFVIII preparation comprising, when reconstructed with water, 290 mM glycine, 20 mM histidine, 30 mM sucrose, 30 mM NaCL, 2.5 mM CaCl2, and 50 to 1500 IU rFVIII / ml

CO97039171A 1996-07-12 1997-07-11 PREPARATION OF ALBUMIN FREE RECOMBINANT FACTOR WHICH HAS A LOW SUGAR CONTENT CO4700302A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/678,492 US5763401A (en) 1996-07-12 1996-07-12 Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Publications (1)

Publication Number Publication Date
CO4700302A1 true CO4700302A1 (en) 1998-12-29

Family

ID=24723010

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97039171A CO4700302A1 (en) 1996-07-12 1997-07-11 PREPARATION OF ALBUMIN FREE RECOMBINANT FACTOR WHICH HAS A LOW SUGAR CONTENT

Country Status (30)

Country Link
US (2) US5763401A (en)
EP (1) EP0818204B1 (en)
JP (1) JP4077055B2 (en)
KR (1) KR100491281B1 (en)
CN (1) CN1130224C (en)
AR (1) AR007845A1 (en)
AT (1) ATE191146T1 (en)
AU (1) AU718901B2 (en)
BR (1) BR9704407B1 (en)
CA (1) CA2210038C (en)
CO (1) CO4700302A1 (en)
CZ (1) CZ292183B6 (en)
DE (1) DE69701548T2 (en)
DK (1) DK0818204T3 (en)
ES (1) ES2144293T3 (en)
GR (1) GR3033669T3 (en)
HU (1) HU221415B1 (en)
ID (1) ID19074A (en)
IL (1) IL121273A (en)
MY (1) MY125544A (en)
NZ (1) NZ328297A (en)
PL (1) PL186950B1 (en)
PT (1) PT818204E (en)
RU (1) RU2201252C2 (en)
SG (1) SG50864A1 (en)
SK (1) SK282207B6 (en)
TR (1) TR199700628A2 (en)
TW (1) TW381027B (en)
UA (1) UA43882C2 (en)
ZA (1) ZA976167B (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2541470T3 (en) * 1999-02-22 2015-07-20 University Of Connecticut Albumin free factor VIII formulations
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ATE319424T1 (en) * 1999-12-30 2006-03-15 Intermune Inc GAMMA-IFN LIQUID DROPS AEROSOL AND METHOD
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
JP2005530683A (en) * 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Liquid composition of factor VII polypeptide
DE10211227A1 (en) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Process for the reconstitution of lyophilized proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
CN101912601B (en) * 2002-06-21 2012-08-29 诺和诺德医疗保健公司 Stabilised solid compositions of factor VII polypeptides
DE60317822D1 (en) * 2002-10-29 2008-01-10 Alza Corp STABILIZED SOLID POLYPEPTIDE PARTICLES
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
WO2005028496A2 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
JP2007534633A (en) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド Human alpha 1-antitrypsin preparation
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
CA2554018A1 (en) * 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
ES2347902T3 (en) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 SOLID PHASE FOR USE IN A PROCEDURE FOR PURIFICATION OF ALBUMINE CONJUGATES.
EP1750733B1 (en) * 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
KR100624013B1 (en) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 Lyophilized Albumin-Free Recombinant Human Coagulation Factor 8 Formulation
SI1778723T1 (en) * 2004-08-17 2013-02-28 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
ES2434035T3 (en) 2004-12-27 2013-12-13 Baxter International Inc. Polymer-von Willebrand factor conjugates
NZ561144A (en) * 2005-03-04 2009-09-25 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
EP1861116B1 (en) 2005-03-25 2015-09-16 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
BRPI0618893A2 (en) * 2005-11-22 2011-09-13 Wyeth Corp immunoglobulin fusion protein formulations
WO2007071068A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
DK1969004T3 (en) 2005-12-28 2011-11-28 Novo Nordisk As Insulin compositions and method of making a composition
DK2364691T3 (en) 2006-06-16 2013-07-01 Regeneron Pharma VEGF antagonist formulations that can be used for intravitreal administration
RU2324495C1 (en) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Method of making preparation of human blood coagulaton factor viii
ES2655639T3 (en) 2006-12-15 2018-02-21 Baxalta GmbH Conjugate of factor VIIa - (poly) sialic acid that has a prolonged half-life in vivo
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
JP5401446B2 (en) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー Stabilization of recombinant protein solutions for cryopreservation
MX2009012964A (en) * 2007-06-01 2010-01-14 Acologix Inc High temperature stable peptide formulation.
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
MX2011002316A (en) * 2008-09-03 2011-05-10 Octapharma Ag New protecting compositions for recombinantly produced factor viii.
BRPI0919946A2 (en) 2008-10-30 2016-02-16 Novo Nordisk As diabetes mellitus treatment using insulin injections with less than daily injection frequency
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
MY199187A (en) 2009-06-09 2023-10-19 Prolong Pharmaceuticals Llc Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
HRP20191793T1 (en) 2010-10-27 2019-12-27 Novo Nordisk A/S TREATMENT OF MELITUS DIABETES BY INSULIN INJECTIONS USED AT DIFFERENT INJECTION INTERVALS
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
JP5943939B2 (en) * 2010-12-28 2016-07-05 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ Fabric made from fluorinated polyester blend yarn
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
CN102430116A (en) * 2011-08-19 2012-05-02 上海新兴医药股份有限公司 Dry heat treatment method for human blood coagulation factor VIII preparation and stabilizing agent thereof
ES2776195T3 (en) 2013-03-15 2020-07-29 Bioverativ Therapeutics Inc Factor VIII polypeptide formulations
WO2014152530A1 (en) 2013-03-15 2014-09-25 Bayer Healthcare Llc Variant factor viii polypeptides and methods of their production and use
BR112015022730A2 (en) * 2013-03-15 2017-10-31 Bayer Healthcare Llc rfviii formulations, method for covalent conjugation of rfviii to a biocompatible polymer and use of rfviii in the preparation of rfviii formulation for treating hemophilia a
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
JP2017509659A (en) * 2014-04-01 2017-04-06 アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ Low sugar-low glycine stable factor VIII formulation
JP2017509658A (en) 2014-04-01 2017-04-06 アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ Stabilization of factor VIII without the use of calcium additives
MX375557B (en) 2014-07-18 2025-03-06 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
EP3177317B1 (en) * 2014-08-04 2020-03-18 CSL Limited Factor viii formulation
US10568948B2 (en) 2015-05-13 2020-02-25 Agenus Inc. Vaccines for treatment and prevention of cancer
BR112018008319A2 (en) * 2015-11-05 2018-10-30 Novo Nordisk A/S fviii formulation
CN106139127B (en) * 2016-08-05 2020-04-07 无锡药明生物技术股份有限公司 Recombinant blood coagulation factor VIII freeze-dried preparation
JP2021522239A (en) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド Heat shock protein-binding peptide composition and how to use it
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US20220389082A1 (en) 2019-07-04 2022-12-08 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4847362A (en) * 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4001451A1 (en) * 1990-01-19 1991-08-01 Octapharma Ag STABLE INJECTABLE SOLUTIONS OF FACTOR VIII AND FACTOR IX
DE4111393A1 (en) * 1991-04-09 1992-10-15 Behringwerke Ag STABILIZED FACTOR VIII PREPARATIONS
EP0638091B1 (en) * 1992-04-30 2005-12-07 Probitas Pharma Inc. Improved solubilization and stabilization of factor viii complex
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
JP3905921B2 (en) * 1992-10-02 2007-04-18 ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー COMPOSITION CONTAINING COAGULATION FACTOR VIII, METHOD FOR PRODUCING THE SAME, AND METHOD FOR USING SURFACTANT AS STABILIATOR
SE9301581D0 (en) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab PROTEIN FORMULATION
SE504074C2 (en) * 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9501189D0 (en) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Also Published As

Publication number Publication date
HU221415B1 (en) 2002-09-28
EP0818204A3 (en) 1998-02-04
TW381027B (en) 2000-02-01
SK282207B6 (en) 2001-12-03
CA2210038A1 (en) 1998-01-12
BR9704407A (en) 2000-06-06
HU9701191D0 (en) 1997-08-28
MY125544A (en) 2006-08-30
KR980008241A (en) 1998-04-30
PL321058A1 (en) 1998-01-19
EP0818204A2 (en) 1998-01-14
CN1181974A (en) 1998-05-20
UA43882C2 (en) 2002-01-15
AU2860497A (en) 1998-01-22
DE69701548T2 (en) 2000-07-27
HUP9701191A2 (en) 1999-06-28
TR199700628A2 (en) 1998-01-21
MX9705209A (en) 1998-05-31
JPH1067679A (en) 1998-03-10
SG50864A1 (en) 1998-07-20
AR007845A1 (en) 1999-11-24
NZ328297A (en) 1999-09-29
US5874408A (en) 1999-02-23
HUP9701191A3 (en) 2000-08-28
IL121273A (en) 2000-09-28
CN1130224C (en) 2003-12-10
CZ292183B6 (en) 2003-08-13
CA2210038C (en) 2007-03-13
ZA976167B (en) 1998-02-02
ES2144293T3 (en) 2000-06-01
CZ219497A3 (en) 1998-01-14
AU718901B2 (en) 2000-04-20
IL121273A0 (en) 1998-01-04
KR100491281B1 (en) 2005-08-05
RU2201252C2 (en) 2003-03-27
PT818204E (en) 2000-08-31
ATE191146T1 (en) 2000-04-15
JP4077055B2 (en) 2008-04-16
US5763401A (en) 1998-06-09
GR3033669T3 (en) 2000-10-31
DK0818204T3 (en) 2000-07-17
ID19074A (en) 1998-06-11
SK92197A3 (en) 1998-02-04
BR9704407B1 (en) 2010-03-09
EP0818204B1 (en) 2000-03-29
PL186950B1 (en) 2004-04-30
DE69701548D1 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
CO4700302A1 (en) PREPARATION OF ALBUMIN FREE RECOMBINANT FACTOR WHICH HAS A LOW SUGAR CONTENT
RU97111733A (en) SUSTAINABLE, ALBUMINE FREE LIOPHILIZED COMPOSITION OF RECOMBINANT FACTOR VIII
EE04481B1 (en) A peptide and adjuvant based pharmaceutical composition for immune modulation
IL142216A0 (en) A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
EP0950665A4 (en) Modified physiologically active proteins and medicinal compositions containing the same
DE69428521D1 (en) MEDICINAL COMPOSITIONS CONTAINING A BACTERICIDAL PERMEABILITY-INCREASING PROTEIN AND A SURFACTANT
DOP2001000197A (en) STABILIZED INTERLEUQUINA-2
GR3030146T3 (en) Stable lyophilized formulation containing a protein and dosage kit.
ES8704350A1 (en) Conjugate constituted by a proteic surface adhesive of Streptococcus mutans, and by a polysaccharide of Streptococcus mutans, its preparation and its use, particularly in anti-caries vaccines.
UA70296A (en) Lyophilized composition comprising liophilic liposomes with incorporated biologically-active principle which is highly insoluble in water
DE3875108D1 (en) PHYSIOLOGICALLY ACTIVE POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION.
EP0422125A4 (en) Platelet blocking peptides
IL84484A0 (en) T-cell suppressor protein in pure form,its preparation by recombinant methods and pharmaceutical compositions containing it
TR199902575T2 (en) Stable pharmaceutical administration form for peptides, proteins and nucleic acids.
IT1290817B1 (en) SOLUBLE SWEETENER COMPOSITION CONTAINING FOOD FIBERS ITS PREPARATION AND USE FOR FOOD PURPOSES
CO5050337A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING IL-18 POLYPEPTIDES AND SAME PREPARATION
GB9726343D0 (en) The use of excipients to accelerate freeze-drying
EP1015553A4 (en) RECOMBINANT bHLH-PAS/JHR POLYPEPTIDE AND ITS USE TO SCREEN POTENTIAL INSECTICIDES
ATE215361T1 (en) LIPOSOMES WITH MULTI-BRANCHED PEPTIDE CONSTRUCTIONS FOR USE AGAINST HIV
NZ219192A (en) Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines
FR2629785B1 (en) LIGHT HIKING BOAT HAVING PIVOTABLE SLEEPERS AND A TENT
EE9900178A (en) Interleukin-1ß Converting Enzyme Peptide, its Use and Pharmaceutical Composition
BR7601302U (en) Constructive arrangement in sealed envelope
TR28011A (en) Purified / pure streptogramin and its preparation.
ATE81531T1 (en) BIOLOGICALLY ACTIVE PEPTIDES TAN-866.